Compare KVYO & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KVYO | LGND |
|---|---|---|
| Founded | 2012 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3B | 3.7B |
| IPO Year | 2023 | N/A |
| Metric | KVYO | LGND |
|---|---|---|
| Price | $13.16 | $270.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 7 |
| Target Price | $34.48 | ★ $256.29 |
| AVG Volume (30 Days) | ★ 5.4M | 175.9K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 35.29 | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | ★ $1,234,019,000.00 | N/A |
| Revenue This Year | $24.47 | $1.25 |
| Revenue Next Year | $19.66 | $19.41 |
| P/E Ratio | $448.31 | ★ $76.27 |
| Revenue Growth | ★ 31.63 | N/A |
| 52 Week Low | $13.38 | $111.72 |
| 52 Week High | $36.76 | $267.27 |
| Indicator | KVYO | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 34.72 | 79.02 |
| Support Level | N/A | $199.97 |
| Resistance Level | $21.74 | N/A |
| Average True Range (ATR) | 0.92 | 7.65 |
| MACD | -0.12 | 2.78 |
| Stochastic Oscillator | 1.47 | 94.27 |
Klaviyo Inc is a technology company that provides a software-as-a-service (SaaS) platform to enable its customers to send the right messages at the right time across email, short message service, and push notifications, more accurately measure and predict performance, and deploy specific actions and campaigns. The platform combines proprietary data and application layers into one solution with machine learning and artificial intelligence capabilities. It is focused on marketing automation within eCommerce as its first application use case. It generates revenue through the sale of subscriptions to its customers for the use of its platform. Geographically, the company generates the majority of its revenue from the Americas, followed by EMEA and APAC.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.